{"prompt": "['Novartis', 'Confidential', 'Page 27', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '33. Patients with uncontrolled diabetes having an HbAlc test result 8% at the Screening', 'Visit laboratory test.', '34. Patients who have a clinically significant laboratory abnormality at the', 'Screening laboratory test including (but not limited to):', 'Total white blood cell count <2500 cells/L', 'AST or ALT>2.0 X ULN or total bilirubin >1.3 X ULN', 'Estimated Glomerular Filtration Rate (eGFR) by the Modification of Diet in Renal', 'Disease (MDRD) equation or Bedside Schwartz equation <55 mL/minute/1.73 m2', '35. Patients who, in the judgement of the investigator, have a clinically significant condition', 'such as (but not limited to) unstable ischemic heart disease, NYHA Class III/IV left', 'ventricular failure, arrhythmia, uncontrolled hypertension, cerebrovascular disease,', 'neurodegenerative diseases, or other neurological disease, uncontrolled hypo- and', 'hyperthyroidism and other autoimmune diseases, hypokalemia, hyperadrenergic state, or', 'ophthalmologic disorder or patients with a medical condition that might compromise', 'patient safety or compliance, interfere with evaluation, or preclude completion of the', 'study.', '36. Patients who have smoked or inhaled any substance other than asthma medications within', 'the 6 month period prior to Screening, or who have a smoking history of greater than 10', 'pack years (Note: 10 pack years = 1 pack /day X 10 yrs., or 1/2 pack/day X 20 yrs.).', '37. Patients with a history of myocardial infarction within 12 months of Screening.', '38. Patients with serious co-morbidities including, but not limited to, neurodegenerative', 'diseases, rheumatoid arthritis and other autoimmune diseases.', '39. Patients with a history of alcohol or drug abuse within 12 months prior to Screening.', '40. Patients with a weight <30 kg.', '41. Patients with a known history of non-compliance to medication.', '42. Patients with a history of being unable to swallow tablets.', '43. Patients who have a history of or current treatment for hepatic disease including but not', 'limited to acute or chronic hepatitis, cirrhosis or hepatic failure.', '44. Patients with a history of immunodeficiency disease or hepatitis B or hepatitis C.', '45. No person directly associated with the administration of the study is allowed to participate', 'as a study subject.', '46. No family member of the investigational study staff is allowed to participate in this study.', '47. History of lactose or milk sensitivity.', '48. Patients with a history of conditions other than asthma that could result in elevated', 'eosinophils (e.g., hypereosinophilic syndromes, Churg-Strauss Syndrome, eosinophilic', 'esophagitis). Patients with known parasitic infestation within 6 months prior to Screening', 'are also excluded.', '49. Patients requiring SCS use for conditions other than asthma (chronic or intermittent) or', 'nasal polyposis.', 'No additional exclusions may be applied by the Investigator, in order to ensure that the study', 'population will be representative of all eligible subjects']['Novartis', 'Confidential', 'Page 28', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '6', 'Treatment', '6.1', 'Study treatment', '6.1.1', 'Investigational and control drugs', 'The following investigational treatment will be supplied by Novartis to the study sites:', 'Name: fevipiprant (labeled as QAW039)', 'Formulation: tablet', 'Unit dose: 2 strengths: 150 mg and 450 mg', \"Please refer to the Investigator's Brochure for composition of the fevipiprant tablets.\", 'Name: fevipiprant placebo', 'Formulation: tablet', 'Unit dose: matching placebo to fevipiprant 150 mg, matching placebo to fevipiprant 450', 'mg', \"Please refer to the Investigator's Brochure for composition of the placebo tablets.\", 'The investigational treatment (tablets) will be supplied in bottles. The matching placebos for', 'fevipiprant will be identical in appearance to their active counterparts and will be identically', 'packaged.', '6.1.2', 'Additional study treatments', 'At the start of the Run-in period, all patients will be provided with mometasone furoate', 'nasal spray (no specific brand required) as the SoC for use during the study. This will either be', 'supplied to the Investigator sites by Novartis or sourced locally and reimbursed by Novartis.', 'All patients will remain on their current asthma treatment for the duration of the study (with the', 'exception of LTRAs, which should be discontinued prior to patients entering the Run-in period).', 'Patients will also be provided with short-acting \u00df2-agonists (SABAs),', '(salbutamol/albuterol/othe SABA) which they will be instructed to use throughout the study as', \"rescue medication to treat asthma symptoms on an 'as needed basis'. SABAs will either be\", 'supplied to the Investigator sites by Novartis or sourced locally and reimbursed by Novartis.', 'Should patients develop any sino-nasal exacerbations during the course of the study, the treating', 'physician should follow their normal treatment regimen with systemic corticosteroids and/or', 'antibiotics.', '6.1.3', 'Treatment arms/group', 'Subjects will be assigned at the randomization visit to one of the following 3 treatment arms in', 'a ratio of 1:1:1.', 'During the Run-in period, all patients will receive the NP SoC treatment only - Mometasone', 'Furoate 200 g once daily, administered as two 50 g actuations into each nostril.', 'For the treatment period, patients will be assigned to one of three treatment arms as follows in', 'a 1:1:1 ratio:']\n\n###\n\n", "completion": "END"}